-
Article
Open AccessCorrection: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
Following the publication of this article, the authors noted that the pomalidomide dose for the additional SC cohort in Fig. 1 was incorrectly listed. The correct dose for pomalidomide in the additional SC coh...
-
Article
Open AccessEfficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes
Autologous stem cell transplantation (ASCT) is a standard treatment for eligible multiple myeloma (MM) patients, but many patients will relapse after ASCT and require subsequent therapy. The proteasome inhibit...
-
Article
Open AccessPomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
This phase 1 dose-escalation study evaluated pomalidomide, bortezomib (subcutaneous (SC) or intravenous (IV)) and low-dose dexamethasone (LoDEX) in lenalidomide-refractory and proteasome inhibitor-exposed rela...
-
Article
Open AccessOutcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up
In Eastern Cooperative Oncology Group-ACRIN E4A03, on completion of four cycles of therapy, newly diagnosed multiple myeloma patients had the option of proceeding to autologous peripheral blood stem cell trans...
-
Article
Erratum: Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
Correction to: Blood Cancer Journal (2014) 4, e182; doi:10.1038/bcj.2014.1; published online 21 February 2014 Since the publication of this article, the authors have identified an error concerning one of the a...
-
Article
Open AccessVorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
The addition of vorinostat to lenalidomide/dexamethasone represents a novel combination therapy in multiple myeloma (MM), informed by laboratory studies suggesting synergy. This was a phase I, multicenter, ope...
-
Article
Open AccessTreatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
Several cytogenetic abnormalities are associated with poor outcomes in multiple myeloma (MM). We prospectively analyzed the impact of cytogenetic abnormalities on outcomes during the phase 2 PX-171-003-A1 stud...
-
Chapter
Myc/Max Family of Transcription Factors and bcl-2 are Involved in Drug-induced Apoptosis of Myeloma Cells
Cell homeostasis is controlled by a balance between proliferation, growth arrest and apoptosis. It is becoming increasingly evident that dysregulation of genes that control apoptosis contributes to the pathoge...
-
Chapter
Specificity and Developmental Changes of an Endogenous Inhibitor of Ceramide Galactosyltransferase
Galactocerebrosides are characteristic components of the myelin sheeth of both central and peripheral nervous system. Two possible pathways have been proposed for their biosynthesis: one through psychosine whi...
-
Chapter
Nervous System Origin of Renal Galactosylceramide in the Twitcher Mouse Mutant
Globoid cell leukodystrophy (GLD, Krabbe disease) is a rare genetic disorder caused by a catalyc deficiency of galactosylceramide (EC 3.2.1.46) (Suzuki and Suzuki, 1970). One of the unusual features of the dis...
